Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Urinary type IV collagen excretion is involved in the decline in estimated glomerular filtration rate in the Japanese general population without diabetes: A 5-year observational study.

Kishi F, Nagai K, Takamatsu N, Tominaga T, Tamaki M, Shibata E, Murakami T, Kishi S, Abe H, Koezuka Y, Minagawa N, Ichien G, Doi T.

PLoS One. 2018 Apr 6;13(4):e0195523. doi: 10.1371/journal.pone.0195523. eCollection 2018. Erratum in: PLoS One. 2018 Jun 21;13(6):e0199401.

2.

Urinary IgG4 and Smad1 Are Specific Biomarkers for Renal Structural and Functional Changes in Early Stages of Diabetic Nephropathy.

Doi T, Moriya T, Fujita Y, Minagawa N, Usami M, Sasaki T, Abe H, Kishi S, Murakami T, Ouchi M, Ichien G, Yamamoto K, Ikeda H, Koezuka Y, Takamatsu N, Shima K, Mauer M, Nagai K, Tominaga T.

Diabetes. 2018 May;67(5):986-993. doi: 10.2337/db17-1043. Epub 2018 Feb 28.

PMID:
29490904
3.

Vascular allografts are resistant to methicillin-resistant Staphylococcus aureus through indoleamine 2,3-dioxygenase in a murine model.

Saito A, Motomura N, Kakimi K, Narui K, Noguchi N, Sasatsu M, Kubo K, Koezuka Y, Takai D, Ueha S, Takamoto S.

J Thorac Cardiovasc Surg. 2008 Jul;136(1):159-67. doi: 10.1016/j.jtcvs.2008.01.006. Epub 2008 May 22.

4.

NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells.

Kenna T, Golden-Mason L, Porcelli SA, Koezuka Y, Hegarty JE, O'Farrelly C, Doherty DG.

J Immunol. 2003 Aug 15;171(4):1775-9. Erratum in: J Immunol. 2003 Nov 15;171(10):5631. Mason Lucy Golden [corrected to Golden-Mason Lucy].

5.

Delineation of a CD1d-restricted antigen presentation pathway associated with human and mouse intestinal epithelial cells.

van de Wal Y, Corazza N, Allez M, Mayer LF, Iijima H, Ryan M, Cornwall S, Kaiserlian D, Hershberg R, Koezuka Y, Colgan SP, Blumberg RS.

Gastroenterology. 2003 May;124(5):1420-31.

PMID:
12730881
6.

The CD1d natural killer T-cell antigen presentation pathway is highly conserved between humans and rhesus macaques.

Kashiwase K, Kikuchi A, Ando Y, Nicol A, Porcelli SA, Tokunaga K, Omine M, Satake M, Juji T, Nieda M, Koezuka Y.

Immunogenetics. 2003 Feb;54(11):776-81. Epub 2003 Feb 6.

PMID:
12618910
7.
8.

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.

Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M.

J Exp Med. 2002 Mar 4;195(5):617-24.

9.

Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.

Singh AK, Wilson MT, Hong S, Olivares-Villagómez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L.

J Exp Med. 2001 Dec 17;194(12):1801-11.

10.

Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis.

Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V.

J Exp Med. 2001 Dec 17;194(12):1789-99.

11.

Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets.

Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y, Balk SB, Strominger JL, Clare-Salzer M, Wilson SB.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13838-43. Epub 2001 Nov 13.

12.

Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases.

Chiodoni C, Stoppacciaro A, Sangaletti S, Gri G, Cappetti B, Koezuka Y, Colombo MP.

Eur J Immunol. 2001 Oct;31(10):3101-10.

PMID:
11592087
13.

Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA.

J Immunol. 2001 Oct 1;167(7):4046-50.

14.

Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.

Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A.

Nat Med. 2001 Sep;7(9):1057-62.

PMID:
11533711
15.

The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.

Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y, Van Kaer L.

Nat Med. 2001 Sep;7(9):1052-6.

PMID:
11533710
16.

In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.

Kikuchi A, Nieda M, Schmidt C, Koezuka Y, Ishihara S, Ishikawa Y, Tadokoro K, Durrant S, Boyd A, Juji T, Nicol A.

Br J Cancer. 2001 Sep 1;85(5):741-6.

17.

CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus.

Exley MA, Bigley NJ, Cheng O, Tahir SM, Smiley ST, Carter QL, Stills HF, Grusby MJ, Koezuka Y, Taniguchi M, Balk SP.

J Leukoc Biol. 2001 May;69(5):713-8. Erratum in: J Leukoc Biol 2001 Aug;70(2):340.

PMID:
11358978
18.

TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.

Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, Tokunaga K, Suzuki K, Kayagaki N, Yagita H, Hirai H, Juji T.

Blood. 2001 Apr 1;97(7):2067-74.

19.

Dendritic cells rapidly undergo apoptosis in vitro following culture with activated CD4+ Valpha24 natural killer T cells expressing CD40L.

Nieda M, Kikuchi A, nicol A, Koezuka Y, Ando Y, Ishihara S, Lapteva N, Yabe T, Tokunaga K, Tadokoro K, Juji T.

Immunology. 2001 Feb;102(2):137-45.

20.

Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography.

Karadimitris A, Gadola S, Altamirano M, Brown D, Woolfson A, Klenerman P, Chen JL, Koezuka Y, Roberts IA, Price DA, Dusheiko G, Milstein C, Fersht A, Luzzatto L, Cerundolo V.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3294-8.

21.

MHC-II-independent CD4+ T cells induce colitis in immunodeficient RAG-/- hosts.

Trobonjaca Z, Leithäuser F, Möller P, Bluethmann H, Koezuka Y, MacDonald HR, Reimann J.

J Immunol. 2001 Mar 15;166(6):3804-12.

22.

Glycolipid antigen processing for presentation by CD1d molecules.

Prigozy TI, Naidenko O, Qasba P, Elewaut D, Brossay L, Khurana A, Natori T, Koezuka Y, Kulkarni A, Kronenberg M.

Science. 2001 Jan 26;291(5504):664-7.

23.

Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.

van der Vliet HJ, Nishi N, Koezuka Y, von Blomberg BM, van den Eertwegh AJ, Porcelli SA, Pinedo HM, Scheper RJ, Giaccone G.

J Immunol Methods. 2001 Jan 1;247(1-2):61-72.

PMID:
11150537
24.

IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells.

Leite-De-Moraes MC, Hameg A, Pacilio M, Koezuka Y, Taniguchi M, Van Kaer L, Schneider E, Dy M, Herbelin A.

J Immunol. 2001 Jan 15;166(2):945-51.

25.

Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells.

Nakagawa R, Serizawa I, Motoki K, Sato M, Ueno H, Iijima R, Nakamura H, Shimosaka A, Koezuka Y.

Oncol Res. 2000;12(2):51-8.

PMID:
11132924
26.

Functional natural killer T cells in experimental mouse strains, including NK1.1- strains.

Serizawa I, Koezuka Y, Amao H, Saito TR, Takahashi KW.

Exp Anim. 2000 Jul;49(3):171-80.

27.

Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells.

Spada FM, Borriello F, Sugita M, Watts GF, Koezuka Y, Porcelli SA.

Eur J Immunol. 2000 Dec;30(12):3468-77.

28.

NKT lymphocyte ontogeny and function are impaired in low antibody-producer Biozzi mice: gene mapping in the interval-specific congenic strains raised for immunomodulatory genes.

Araujo LM, Puel A, Gouarin C, Hameg A, Mevel JC, Koezuka Y, Bach JF, Mouton D, Herbelin A.

Int Immunol. 2000 Nov;12(11):1613-22.

PMID:
11058581
29.

A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.

Hameg A, Apostolou I, Leite-De-Moraes M, Gombert JM, Garcia C, Koezuka Y, Bach JF, Herbelin A.

J Immunol. 2000 Nov 1;165(9):4917-26.

30.

Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes.

Leite-de-Moraes MC, Herbelin A, Gouarin C, Koezuka Y, Schneider E, Dy M.

J Immunol. 2000 Oct 15;165(8):4367-71.

31.

Natural killer T cell activation inhibits hepatitis B virus replication in vivo.

Kakimi K, Guidotti LG, Koezuka Y, Chisari FV.

J Exp Med. 2000 Oct 2;192(7):921-30.

32.

Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers.

Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, Koezuka Y, Kronenberg M.

J Exp Med. 2000 Sep 4;192(5):741-54.

33.

Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro.

Ishihara S, Nieda M, Kitayama J, Osada T, Yabe T, Kikuchi A, Koezuka Y, Porcelli SA, Tadokoro K, Nagawa H, Juji T.

J Immunol. 2000 Aug 1;165(3):1659-64.

34.

alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria.

Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T, Taniguchi M, Bendelac A, Van Kaer L, Koezuka Y, Tsuji M.

Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8461-6.

35.

Neonatal invariant Valpha24+ NKT lymphocytes are activated memory cells.

D'Andrea A, Goux D, De Lalla C, Koezuka Y, Montagna D, Moretta A, Dellabona P, Casorati G, Abrignani S.

Eur J Immunol. 2000 Jun;30(6):1544-50.

36.

Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice.

Saubermann LJ, Beck P, De Jong YP, Pitman RS, Ryan MS, Kim HS, Exley M, Snapper S, Balk SP, Hagen SJ, Kanauchi O, Motoki K, Sakai T, Terhorst C, Koezuka Y, Podolsky DK, Blumberg RS.

Gastroenterology. 2000 Jul;119(1):119-28.

PMID:
10889161
37.

CD1-mediated antigen presentation of glycosphingolipids.

Naidenko OV, Koezuka Y, Kronenberg M.

Microbes Infect. 2000 May;2(6):621-31. Review.

PMID:
10884613
38.

Synthesis of NBD-alpha-galactosylceramide and its immunologic properties.

Sakai T, Ehara H, Koezuka Y.

Org Lett. 1999 Aug 12;1(3):359-61.

PMID:
10822576
39.

Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells.

Takahashi T, Nieda M, Koezuka Y, Nicol A, Porcelli SA, Ishikawa Y, Tadokoro K, Hirai H, Juji T.

J Immunol. 2000 May 1;164(9):4458-64.

40.

[Anti-tumor activity of KRN7000, an alpha-galactosylceramide and its action mechanism].

Kobayashi E, Koezuka Y.

Tanpakushitsu Kakusan Koso. 2000 Apr;45(6 Suppl):1193-8. Review. Japanese. No abstract available.

PMID:
10771695
41.

Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.

Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S, Juji T.

Exp Hematol. 2000 Mar;28(3):276-82.

PMID:
10720692
42.

Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+V beta 11+ T cells in vitro.

Nishi N, van der Vliet HJ, Koezuka Y, von Blomberg BM, Scheper RJ, Pinedo HM, Giaccone G.

Hum Immunol. 2000 Apr;61(4):357-65.

PMID:
10715513
43.

Murine CD1d-restricted T cell recognition of cellular lipids.

Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, Koezuka Y, Porcelli SA, Cardell S, Brenner MB, Behar SM.

Immunity. 2000 Feb;12(2):211-21.

44.
45.

Effects of alpha-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Valpha24+ Vbeta11+ T cells.

Van Der Vliet HJ, Nishi N, Koezuka Y, Peyrat MA, Von Blomberg BM, Van Den Eertwegh AJ, Pinedo HM, Giaccone G, Scheper RJ.

Immunology. 1999 Dec;98(4):557-63.

46.

A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement.

Leite-De-Moraes MC, Hameg A, Arnould A, Machavoine F, Koezuka Y, Schneider E, Herbelin A, Dy M.

J Immunol. 1999 Dec 1;163(11):5871-6.

47.

Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells.

Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A.

J Immunol. 1999 Nov 1;163(9):4647-50.

48.

Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.

Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, Koezuka Y, Van Kaer L.

J Immunol. 1999 Sep 1;163(5):2373-7.

49.

Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice.

Hong S, Scherer DC, Singh N, Mendiratta SK, Serizawa I, Koezuka Y, Van Kaer L.

Immunol Rev. 1999 Jun;169:31-44. Review.

PMID:
10450506
50.

A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.

Tomura M, Yu WG, Ahn HJ, Yamashita M, Yang YF, Ono S, Hamaoka T, Kawano T, Taniguchi M, Koezuka Y, Fujiwara H.

J Immunol. 1999 Jul 1;163(1):93-101.

Supplemental Content

Loading ...
Support Center